PRIME: Phase III Study of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome

• Sponsor: Shoichi Maruyama MD PhD (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05914155
• Collaborator: (none)
• Enrollment: 88
• Locations: 8
• Arms: 3
• Anticipated Duration (Months): 42.4
• Patients Per Site: 11
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

To confirm the efficacy and safety of rituximab (genetical recombination) intravenously administered to idiopathic membranous nephropathy with nephrotic syndrome.

Condition or Disease	Intervention/Treatment	Phase
Glomerulonephritis, Membranous; Nephrotic Syndrome，Idiopathic	Drug: Rituximab (genetical recombination); Drug: Placebo; Drug: Rituximab (genetical recombination)	Phase 3

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 88 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: The Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome （PRIME Study）
• Anticipated Study Start Date: Jun 20, 2023
• Anticipated Primary Completion Date: Dec 31, 2026
• Anticipated Study Completion Date: Dec 31, 2026

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Rituximab group in double-blind phase	Drug: Rituximab (genetical recombination); Administer 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses in double-blind phase.
Placebo Comparator: Placebo group in double-blind phase	Drug: Placebo; Administer placebo IV infusion every two weeks for two doses in double-blind phase.
Other: Rituximab group in open-label phase	Drug: Rituximab (genetical recombination); Patients who remain to be ICR II (Incomplete Remission Type II) or NR (No Response) until Week 26 in the double-blind phase, if the patients wish to move to the open-label phase and the investigator or a subinvestigator considers the move necessary, the patient will move to the open-label phase and receive 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses after the readministration criteria are confirmed to be met.

Outcome Measures

Primary Outcome Measures

1. Percentage of patients achieving ICR I [up to 26 weeks]

   Achieving ICR I is defined as "Urine protein-creatinine ratio < 1.0 g/gCr".

Secondary Outcome Measures

1. Percentage of patients who are CR, ICR I, ICR II, NR or PR [up to 26 weeks]

   CR, ICR I, ICR II, NR or PR are defied as below; CR (Complete Remission): Urine protein-creatinine ratio < 0.3 g/gCr ICR I (Incomplete Remission Type I): 0.3 g/gCr ≤ Urine protein-creatinine ratio < 1.0 g/gCr ICR II (Incomplete Remission Type II): 1.0 g/gCr ≤ Urine protein-creatinine ratio < 3.5 g/gCr NR (No Response): 3.5 g/gCr ≤ Urine protein-creatinine ratio PR (Partial Remission): Decrease in urine protein-creatinine ratio from base line ≥50%, and urine protein-creatinine ratio 0.3 to 3.5 g/gCr

2. Duration before achieving CR, ICR I, ICR II or PR [up to 26 weeks]

   Duration of achieving CR, ICR I, ICR II or PR is summarized.

3. Urine protein-creatinine ratio [up to 26 weeks]

   The differences of urine protein-creatinine ratio between prior to treatment and at each timepoint are summarized.

4. eGFR [up to 26 weeks]

   The differences of eGFR between prior to treatment and at each timepoint are summarized.

5. B-cells (CD19-positive and CD20-positive cells) [up to 26 weeks]

   B cell counts (CD19 positive and CD20 positive cell counts) at each timepoint are summarized.

6. Expression of HACA [up to 26 weeks]

   The number of patients expressing HACA, and the proportion of these patients at each timepoint are summarized.

7. Serum rituximab (genetical recombination) concentration [up to 26 weeks]

   Serum rituximab (genetical recombination) level at each timepoint are summarized.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 15 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Patients who undergo kidney biopsy and are diagnosed as having idiopathic membranous nephropathy prior to the obtainment of informed consent

2. Patients who are diagnosed as having nephrotic syndrome prior to the obtainment of informed consent and receive no steroids or immunosuppressants within 12 weeks prior to the obtainment of informed consent

3. Patients with urine protein-creatinine ratio ≥ 3.5 g/gCr at the screening

4. Patients with hypoalbuminemia (serum albumin ≤ 3.0 g/dL) at the screening

5. Patients aged 15 years or older at informed consent

6. Patients who give voluntary written consent after having received adequate information on this study (legally acceptable representatives should also give consent for underage patients, and informed assent should be obtained from children)

Exclusion Criteria:

1. Patients with primary nephrotic syndrome other than membranous nephropathy (IgA nephropathy, minimal change disease, focal segmental glomerulosclerosis and so forth), and patients with secondary nephrotic syndrome (autoimmune disease, metabolic disease, infection, allergic/hypersensitive disease, tumor, and drug-induced disease)

2. Patients with the renal function lowered (eGFR <30 mL/min/1.73 m2 based on CKD-EPIcr formula) at the screening

3. Patients who have used anti-CD20 antibody including rituximab (genetical recombination) prior to the informed consent for idiopathic membranous nephropathy

4. Patients who have participated in another clinical study within 12 weeks prior to the informed consent (enrollment is allowed for those participating in a clinical study in the range of 'Indications' or 'Dosage and Administration' in Japan) or patients who are participating in another study

5. Patients with history of renal transplant

6. Patients with poorly controlled diabetes (HbA1c of 8.0% or higher)

7. Patients who have or are suspected to have active infection (infection requiring treatment with systemic antimicrobial, antifungal, or antiviral agents) at the time of the screening

8. Patients tested positive for HBs antigen, HBs antibody, HBc antibody, and/or HCV antibody (patients with positive HBs antibody and/or HBc antibody can be enrolled only when HBV-DNA test is negative [less than the detection limit]), or patients with positive HIV antibody or HTLV-1 antibody at the time of the screening

9. Patients with leukopenia (less than 2,000 /mm3), neutropenia (less than 1,000 /mm3), or lymphopenia (less than 500 /mm3) at the time of the screening

10. Patients with history of serious hypersensitivity or anaphylactic reaction to one of the ingredients in the investigational drug or murine protein-containing products

11. Patients who are judged to be life-threatening nephrotic syndrome by the investigator or a subinvestigator

12. Patients with serious comorbidity (e.g., hepatic, renal (excluding idiopathic membranous nephropathy with nephrotic syndrome), cardiac, lung, hematologic, or brain disease)

13. Female patients who are pregnant, lactating, or potentially pregnant, or patients who are not willing to use contraceptive measures during the study period

14. Patients who are judged to be unsuitable by the investigator or a subinvestigator

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Anjo Kosei Hospital	Anjo	Aichi	Japan	4468602
2	Kasugai Municipal Hospital	Kasugai	Aichi	Japan	486-8510
3	Konan Kosei Hospital	Kōnan	Aichi	Japan	4838704
4	Juntendo University Urayasu Hospital	Urayasu	Chiba	Japan	2790021
5	Kurume University Hospial	Kurume	Fukuoka	Japan	8300011
6	Mie University Hospial	Tsu	Mie	Japan	5148507
7	Kyushu University Hospital	Fukuoka		Japan	8128582
8	University Hospital,Kyoto Prefectural University of Medicine	Kyoto		Japan	6028566

Sponsors and Collaborators

• Shoichi Maruyama MD PhD

Investigators

• Principal Investigator: Shoichi Shoichi, PhD, MD, Nagoya University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Shoichi Maruyama MD PhD, Professor, Nagoya University
• ClinicalTrials.gov Identifier: NCT05914155
• Other Study ID Numbers: CAMCR-020
• First Posted: Jun 22, 2023
• Last Update Posted: Jun 22, 2023
• Last Verified: Jun 1, 2023

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Nephrotic Syndrome; Nephrosis; Glomerulonephritis; Glomerulonephritis, Membranous; Syndrome; Rituximab

Study Results

No Results Posted as of Jun 22, 2023